Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;127(4):473-485.
doi: 10.1111/bju.15209. Epub 2020 Sep 21.

Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification

Yuki Kohada  1   2 , Tetsutaro Hayashi  2 , Ryan S Hsi  3 , Kazuma Yukihiro  1 , Kazuhiro Sentani  4 , Keisuke Goto  2 , Shogo Inoue  2 , Shinya Ohara  1 , Jun Teishima  2 , Mitsuru Kajiwara  1 , Takashi Nishisaka  5 , Wataru Yasui  4 , Peter C Black  6 , Akio Matsubara  2
Affiliations

Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification

Yuki Kohada et al. BJU Int. 2021 Apr.

Abstract

Objectives: To assess the change in rates of recurrence-free survival (RFS) and progression-free survival (PFS) based on the duration of survival without recurrence or progression among patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), and to examine the predictive factors for recurrence at different time points by assessing conditional RFS and PFS.

Participants and methods: A cohort of 602 patients treated with transurethral resection of bladder tumour and histopathologically diagnosed with IR NMIBC was included in this retrospective study.

Results: The conditional RFS rate at 1, 2, 3, 4 and 5 years improved with increased duration of RFS; however, the conditional PFS rate did not improve over time. Multivariable analyses showed that recurrent tumour, multiple tumours, tumour size (>3 cm), immediate postoperative instillation of chemotherapy, and administration of BCG were independent predictive factors for recurrence at baseline. The predictive ability of these factors disappeared with increasing recurrence-free survivorship. Subclassification of these patients with IR NMIBC into three groups using clinicopathological factors (recurrent tumour, multiple tumours, tumour size) demonstrated that the high IR group (two factors) had significantly worse RFS than the intermediate (one factor, P < 0.001) and low IR groups (no factor, P = 0.005) at baseline. This subclassification stratified conditional risk of RFS also at 1, 3 and 5 years, which provides the basis for distinct surveillance protocols among patients with IR NMIBC.

Conclusion: Conditional survival analyses of patients with IR NMIBC demonstrate that RFS changes over time, while PFS does not change. These data support distinct surveillance protocols based on the subclassification of IR NMIBC.

Keywords: #BladderCancer; #blcsm; #uroonc; #utuc; conditional survival; progression; recurrence; surveillance; urinary bladder cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stenzl A, Cowan NC, De Santis M et al. Treatment of muscle invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-18
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
    1. Ederer IA, Lucca I, Hofbauer SL et al. Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. World J Urol 2015; 33: 2087-93
    1. Babjuk M, Böhle A, Burger M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017; 71: 447-61
    1. Rieken M, Shariat SF, Kluth L et al. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol Oncol 2018; 36: 8.e17-e24

LinkOut - more resources